Here’s the A to Z of every major brand in our ... - GSK
Aquafresh provides dental care and feel good protection for kids and adults with a range of toothpastes, toothbrushes and on-the-move oral care products. Major markets: Global (branded Binaca in Spain, Odol in Czech Republic, Odol-med3 inGermany). Abreva is a range of specialist cold sore products providing a complete regimen from rescue
Download Here’s the A to Z of every major brand in our ... - GSK
Information
Domain:
Source:
Link to this page:
Documents from same domain
Emma Walmsley, CEO - gsk.com
www.gsk.comAgenda 2 Q2 2018 progress (15 mins) Emma Walmsley, Chief Executive Officer Q2 2018 financial results (15 mins) Simon Dingemans, Chief Financial Officer
Audit & Risk Committee Terms of Reference - Home | GSK
www.gsk.comAudit & Risk Committee – Terms of Reference 2 3. Each of the members of the Committee shall be independent Non-Executive Directors, as determined by the Board of the Company, in accordance with the provisions of the UK Corporate
Press release Third quarter 2021
www.gsk.comIssued: Wednesday, 27 October 2021, London, U.K. 3 Operating performance – Q3 2021 Turnover Q3 2021 £m Growth £% Growth CER% Pharmaceuticals 4,397 5 10 Vaccines 2,174 7 13 Consumer Healthcare 2,506 3 8 Group turnover 9,077 5 10 Group turnover was £9,077 million in the quarter, up 5% AER, 10% CER.
Q3 2021 results
www.gsk.comProgressing towards demerger at pace. 8. 1. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. 2021-26 CAGR is for the 5 …
Annual Report 2018 - GSK
www.gsk.comGSK Annual Report 2018 02. Research & development . Success in R&D will always be fundamental to shareholder returns. A renewed focus on R&D was set out by Emma Walmsley when she became CEO in 2017, and a new plan to improve the pipeline of new medicines has now been launched by Dr Hal Barron, our new Chief
Press release Full year and fourth quarter 2020 - GSK
www.gsk.com* Reported AER and CER growth rates for 2020 include five months’ results of the former Pfizer consumer healthcare business in 2019. Pro-forma CER growth rates are calculated as if the equivalent seven months of Pfizer consumer healthcare business results, as reported by Pfizer, were included in the comparative period of 2019.
Annual Report 2019 - GSK
www.gsk.comTrust We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. Our values and expectations Our values – patient focus, transparency, respect and integrity. Our expectations – courage, accountability, development and teamwork.
Financial statements - GSK
www.gsk.comThe Group financial statements for the year ended . 31 December 2020, comprising principal statements and supporting notes, are set out in the ‘Financial statements’ on pages 154 to 237 of this report. The parent company financial statements for the year ended 31 December 2020, comprising the balance sheet and the statement of changes in
Annual Report 2020 - GSK
www.gsk.comframework, we invest in our business to provide shareholder returns. In 2020 we paid a dividend of 80p per share and delivered £5.4 billion of free cash flow. We make a positive contribution to the communities in . which we operate. We employ over 94,000 people across 96 countries and work directly with 36,000 suppliers.
ESG Performance Summary 2020 - GSK
www.gsk.comEmployee turnover Overall turnover (%) – – 12.5 15.7 Calculated as the number of permanent employees that left GSK in 2020 for any reason divided by the average 2020 permanent headcount. Turnover of voluntary leavers (%) – – 6.7 5.6 Calculated as the number of permanent employees that voluntarily left GSK in 2020
Related documents
ICH HARMONISED TRIPARTITE GUIDELINE
database.ich.org1 GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS 1. INTRODUCTION 1.1 Objective This document (Guide) is intended to provide guidance regarding good manufacturing practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under
M3(R2) Step 5 Non-clinical safety studies for conduct of ...
www.ema.europa.euPharmaceuticals under development for indications in life -threatening or serious diseases (e.g., advanced cancer, resistant HIV infection, and congenital enzyme deficiency diseases) without current effective therapy also warrant a case-by-case approach to both the tox icological evaluation and clinical
WHO | World Health Organization
www.who.intWHO | World Health Organization